Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders

References

• Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol (Copenh) 1967; 55: 278–304
   PubMedGoogle Scholar
• Alvarsson M, Grill VE, Wajngot A, Cerasi E, Efendic S. Long-term stability of low insulin responses in non-diabetic subjects. Acta Endocrinol (Copenh) 1992; 127: 33–7
   PubMedGoogle Scholar
• Lindsten J, Cerasi E, Luft R, Morton N, Ryman N. Significance of genetic factors for the plasma insulin response to glucose in healthy subjects. Clin Genet 1976; 10: 125–34
   PubMedGoogle Scholar
• Iselius L, Lindsten J, Morton NE, Efendic S, Cerasi E, Haegermark A, et al. Evidence of an autosomal recessive gene regulating the persistence of the insulin response to glucose in man. Clin Genet 1982; 22: 180–94
   PubMedGoogle Scholar
• Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993; 42: 1663–72
   PubMed Web of Science ®Google Scholar
• Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D, Jr. Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol 1984; 247: E592–6
   Google Scholar
• Grill V, Pigon J, Hartling SC, Binder C, Efendic S. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism 1990; 39: 251–8
   PubMedGoogle Scholar
• Grill V, Alvarsson M, Efendic S. Dexamethasone treatment fails to increase arginine-induced insulin release in healthy subjects with low insulin response. Diabetologia 1992; 35: 367–71
   PubMedGoogle Scholar
• Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Stand 1988; 223: 405–18
   PubMed Web of Science ®Google Scholar
• Canner PL, Bexge KG, Wengez NK, Stamler J, Friedman L, Princas RJ, et al. for the Coronary Drug Project Research Group. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55
   PubMed Web of Science ®Google Scholar
• Miettinen TA, Taskinen M-R, Pellconen R, Nikkilaˇ EA. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 1969; 186: 247–53
   PubMedGoogle Scholar
• McCulloch DK, Kahn SE, Schwartz MW, Koerker DJ, Palmer JP. Etfact of nicotinic acid-induced insulin resistance on pancreatic Bcell function in normal and streptozocin-treated baboons. J Clin Invest 1991; 87: 1395–401
   PubMed Web of Science ®Google Scholar
• Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte D, Jr. Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab 1992; 74: 192–7
   PubMed Web of Science ®Google Scholar
• Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, et al. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38: 562–8
   PubMed Web of Science ®Google Scholar
• Herbert V, Lau KS, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25: 1375–84
   PubMed Web of Science ®Google Scholar
• Faloona GR, Unger RH. Glucagon radioimmunoassay technique. In. Methods of hormone radioimmunoassay, BM Jaffe, HE Behrman. Academic Press, New York 1974; 317–30
   Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–23
   PubMed Web of Science ®Google Scholar
• Mitrakou A, Vuorinen-Markkola H, Raptis G, Toft I, Mokan M, Strumph P, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp. J Clin Endocrinol Metab 1992; 75: 379–82
   PubMed Web of Science ®Google Scholar
• Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D, Jr. Diminished B-cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74: 1318–28
   PubMed Web of Science ®Google Scholar
• Berge KG. Side effects of nicotinic acid in treatment of hypercholesteremia. Geriatrics 1961; 416–22
   Web of Science ®Google Scholar
• Gaut ZN, Solomon HM, Mier ON. The influence of antilipemic doses of nicotinic acid on carbohydrate tolerance and plasma insulin levels in man. Metabolic effects of nicotinic acid and its derivatives, KF Gey, LA Carlson. Hans Huber, Berne 1971; 923–7
   Google Scholar
• Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. J Am Med Assoc 1990; 264: 723–6
   PubMed Web of Science ®Google Scholar
• Löffler G, Trautschold I. Influence of nicotinic acid on insulin secretionin vivo and in vitro. Metabolic effects of nicotinic acid and its derivates, KF Gey, LA Carlson. Hans Huber, Berne 1971; 933–7
   Google Scholar
• Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 1987; 36: 502–6
   PubMed Web of Science ®Google Scholar
• Bonadonna RC, Zych K, Boni C, Ferrannini E, DeFronzo RA. Time dependence of the interaction between lipid and glucose in humans. Am J Physiol 1989; 257: E49–56
   Google Scholar
• Boden G, Jadali F. Effects of lipid on basal carbohydrate metabolism in normal men. Diabetes 1991; 40: 686–92
   PubMedGoogle Scholar
• Nikkill EA, Miettinen TA. Nicotinic acid and gluconeogenesis in man. Metabolic effects of nicotinic acid and its derivatives, KF Gey, LA Carlson. Hans Huber, Berne 1971; 753–5
   Google Scholar
• Fulcher GR, Walker M, Catalano C, Agius L, Aim KGMM. Metabolic effects of suppression of nonesterifid fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 1992; 41: 1400–8
   PubMedGoogle Scholar
• Saloranta C, Taskinen MR, Widén E, Härkönen M, Melander A, Groop L. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993; 42: 1559–66
   PubMed Web of Science ®Google Scholar